ARUP LABORATORIES | aruplab.com
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: 801-583-2787, toll free: 800-522-2787
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

PATIENT REPORT

Patient Age/Sex: Female

Specimen Collected: 12-Sep-23 13:26

CYP2B6 | **Received: 12-Sep-23 13:30** **Report/Verified: 12-Sep-23 15:14**

Procedure	Result	Units	Reference Interval
2B6 Specimen	Whole Blood		
CYP2B6 Genotype	*1/*1		
CYP2B6 Phenotype	Normal		
2B6 Interpretation	See Note f1 i1		
EER CYP2B6	See Note f2		

Result Footnote

f1: 2B6 Interpretation

The following CYP2B6 alleles were detected: *1/*1. This result predicts the normal metabolizer phenotype.

Recommendation: Guidelines for genotype-based dosing are published by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and can be found at: https://cpicpgx.org/ and https://www.pharmgkb.org/.

This result has been reviewed and approved by [redacted]

f2: EER CYP2B6
Authorized individuals can access the ARUP Enhanced Report using the following link:

[redacted]

Test Information

i1: 2B6 Interpretation

BACKGROUND INFORMATION FOR CYP2B6:
CHARACTERISTICS: The cytochrome P450 (CYP) isozyme 2B6 is involved in the metabolism of many drugs. Variants in the gene that codes for CYP2B6 may influence pharmacokinetics of substrates and may predict or explain non-standard dose requirements, therapeutic failure, or adverse reactions.
Inheritance: Autosomal codominant
CAUSE: CYP2B6 gene variants affect enzyme function.
VARIANTS TESTED:
(Variants are numbered according to the following transcripts: CYP2B6 NM_000767).

*1: Indicative of no detected targeted variants and an assumption of functional allele.

CYP2B6*4: rs2279343, c.785A>G
CYP2B6*6: rs3745274, c.516G>T; rs2279343, c.785A>G
CYP2B6*7: rs3745274, c.516G>T; rs2279343, c.785A>G; rs3211371, c.1459C>T
CYP2B6*9: rs3745274, c.516G>T
CYP2B6*18: rs28399499, c.983T>C
CYP2B6*22: rs34223104, c.-82T>C
CYP2B6*36: rs34223104, c.-82T>C; rs3745274, c.516G>T; rs2279343, c.785A>G

CLINICAL SENSITVITY: Drug-dependent.
METHODOLOGY: Polymerase chain reaction (PCR) and fluorescence monitoring

Test Information

i1: 2B6 Interpretation

ANALYTICAL SENSITIVITY AND SPECIFICITY: Greater than 99 percent
LIMITATIONS: Only the targeted CYP2B6 variants will be detected by this test, and assumptions about phase and content are made to assign alleles. Publicly available sources such as the www.pharmvar.org or www.pharmgkb.org provide guidance on phenotype predictions and allele frequencies. Diagnostic errors can occur due to rare sequence variations. Risk of therapeutic failure or adverse reactions with CYP2B6 substrates may be affected by genetic and non-genetic factors that are not detected by this test. This result does not replace the need for therapeutic drug or clinical monitoring.

Please note the information contained in this report does not contain medication recommendations and should not be interpreted as recommending any specific medications. Any dosage adjustments or other changes to medications should be evaluated in consultation with a medical provider.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.